Form 4: Olema Director Sells Shares Under Rule 10b5-1 Plan

Olema Pharmaceuticals Director Cyrus Harmon sold 2,881 shares of common stock for $28.53 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported a sale of common stock.
• The transaction involved the disposition of 2,881 shares of common stock.
• The shares were sold at a weighted average price of $28.53 per share, with prices ranging from $28.50 to $28.53.
• The sale was executed on December 22, 2025.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following the reported transaction, Cyrus Harmon directly beneficially owns 741,259 shares of common stock.
• Additionally, 117,028 shares are indirectly beneficially owned by the Harmon Family Investors LLC, of which Mr. Harmon is the manager.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the explicit mention of a Rule 10b5-1 plan indicates the transaction was pre-scheduled and not based on new, non-public information, thereby mitigating any negative implications.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on new, non-public information, which mitigates concerns about opportunistic insider selling.

Negatives

• The sale by a director reduces their direct ownership stake in the company.

Industry Context

This filing reports a routine insider transaction for a director of a pharmaceutical company. Such transactions are common and often part of personal financial planning, especially when executed under a Rule 10b5-1 plan, and do not typically reflect broader industry trends or competitive positioning.

Related Party Transactions

• Cyrus Harmon indirectly beneficially owns 117,028 shares through the Harmon Family Investors LLC, of which he is the manager.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, although the pre-arranged nature of the sale under a 10b5-1 plan suggests it is a routine financial event rather than a signal of management's view on future performance.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Cyrus Harmon, Director, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan